Study title:
Robel-Tillig, E., et al., Cardiovascular impact of dobutamine in neonates with myocardial dysfunction. Early Hum Dev, 2007. 83(5): p. 307-12.Robel-Tillig, E., et al., Cardiovascular impact of dobutamine in neonates with myocardial dysfunction. Early Hum Dev, 2007. 83(5): p. 307-12.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Cardiovascular Diseases [C14]
|
Brands: |
MAH holders: Please see report |
Assessment: |
Active substance: DOBUTAMINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|